ADAS-Cog11 performance as a surrogate of tau PET burden in an Asian Alzheimer's disease cohort

= 0.20) were significantly associated with global tau SUVr (all p < 0.05). ADAS-Cog11 > 25 discriminated elevated tau burden with good diagnostic performance (AUC = 0.85; sensitivity 61.5%; specificity 90%). Amyloid CL values did not significantly distinguish high tau burden (p = 0.24).ConclusionsADAS-Cog11 provides an accessible complementary indicator of global tau burden independent of amyloid deposition. An ADAS-Cog11 cutoff >25 may aid clinical stratification for anti-amyloid therapies in settings where tau PET is unavailable, supporting scalable and accessible precision assessment in AD care.